156 related articles for article (PubMed ID: 37991939)
21. Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis.
Lohmann AE; Soldera SV; Pimentel I; Ribnikar D; Ennis M; Amir E; Goodwin PJ
J Natl Cancer Inst; 2021 Nov; 113(11):1465-1475. PubMed ID: 33620467
[TBL] [Abstract][Full Text] [Related]
22. Body mass index and absolute lymphocyte count predict disease-free survival in Korean breast cancer patients.
Ko SM; Lee J; Bae SJ; Baik SJ; Ji J; Kim D; Ahn SG; Jeong J
Br J Cancer; 2021 Jul; 125(1):119-125. PubMed ID: 33875823
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
[TBL] [Abstract][Full Text] [Related]
24. Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer.
Van Baelen K; Nguyen HL; Hamy-Petit AS; Richard F; Karsten MM; Nader Marta G; Vermeulen P; Toussaint A; Reyal F; Vincent-Salomon A; Dirix L; Dordevic AD; de Azambuja E; Larsimont D; Amato O; Maetens M; De Schepper M; Geukens T; Han SN; Baert T; Punie K; Wildiers H; Smeets A; Nevelsteen I; Floris G; Biganzoli E; Neven P; Desmedt C
Eur J Cancer; 2023 Sep; 191():112988. PubMed ID: 37573673
[TBL] [Abstract][Full Text] [Related]
25. The impact of obesity and endocrine therapy on the prognosis of premenopausal women with hormone receptor-positive breast cancer: A single-institute retrospective study.
Ozaki Y; Masuda J; Kataoka A; Kogawa T; Abe T; Morizono H; Inagaki L; Hara F; Takano T; Ueno T; Ohno S
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1695. PubMed ID: 36806718
[TBL] [Abstract][Full Text] [Related]
26. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy.
Sinicrope FA; Foster NR; Yothers G; Benson A; Seitz JF; Labianca R; Goldberg RM; Degramont A; O'Connell MJ; Sargent DJ;
Cancer; 2013 Apr; 119(8):1528-36. PubMed ID: 23310947
[TBL] [Abstract][Full Text] [Related]
27. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
Buzdar AU;
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):399-403. PubMed ID: 14623537
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic and Prognostic Significance of Body Mass Index (BMI) among Breast Cancer Patients in Western China: A Retrospective Multicenter Cohort Based on Western China Clinical Cooperation Group (WCCCG).
Wang K; Wu YT; Zhang X; Chen L; Zhu WM; Zhang AJ; Zheng K; Yin XD; Li F; Kong LQ; Ma BL; Li H; Liu JP; Jiang J; Li ZY; Shi Y; Ren GS; Li HY
Biomed Res Int; 2019; 2019():3692093. PubMed ID: 31119166
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.
Pfeiler G; Stöger H; Dubsky P; Mlineritsch B; Singer C; Balic M; Fitzal F; Moik M; Kwasny W; Selim U; Renner K; Ploner F; Steger GG; Seifert M; Hofbauer F; Sandbichler P; Samonigg H; Jakesz R; Greil R; Fesl C; Gnant M;
Br J Cancer; 2013 Apr; 108(7):1408-14. PubMed ID: 23511562
[TBL] [Abstract][Full Text] [Related]
30. Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
Iwase T; Saji S; Iijima K; Higaki K; Ohtani S; Sato Y; Hozumi Y; Hasegawa Y; Yanagita Y; Takei H; Tanaka M; Masuoka H; Tanabe M; Egawa C; Komoike Y; Nakamura T; Ohtsu H; Mukai H
J Clin Oncol; 2023 Jun; 41(18):3329-3338. PubMed ID: 37079878
[TBL] [Abstract][Full Text] [Related]
31. Impact of BMI for clinical outcomes in Japanese breast cancer patients.
Gondo N; Sawaki M; Hattori M; Yoshimura A; Kotani H; Adachi Y; Kataoka A; Sugino K; Mori M; Horisawa N; Terada M; Ozaki Y; Iwata H
Jpn J Clin Oncol; 2020 Mar; 50(3):230-240. PubMed ID: 31958129
[TBL] [Abstract][Full Text] [Related]
32. Impact of African ancestry on the relationship between body mass index and survival in an early-stage breast cancer trial (ECOG-ACRIN E5103).
Ballinger TJ; Jiang G; Shen F; Miller KD; Sledge GW; Schneider BP
Cancer; 2022 Jun; 128(11):2174-2181. PubMed ID: 35285940
[TBL] [Abstract][Full Text] [Related]
33. Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle.
Wolters R; Schwentner L; Regierer A; Wischnewsky M; Kreienberg R; Wöckel A
Breast Cancer Res Treat; 2012 Feb; 131(3):925-31. PubMed ID: 22080246
[TBL] [Abstract][Full Text] [Related]
34. The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies.
Smith SG; Sestak I; Morris MA; Harvie M; Howell A; Forbes J; Cuzick J
Breast Cancer Res Treat; 2021 Jul; 188(1):215-223. PubMed ID: 33656637
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index.
Sendur MA; Aksoy S; Zengin N; Altundag K
Br J Cancer; 2012 Nov; 107(11):1815-9. PubMed ID: 23099804
[TBL] [Abstract][Full Text] [Related]
36. Measured adolescent body mass index and adult breast cancer in a cohort of 951,480 women.
Keinan-Boker L; Levine H; Derazne E; Molina-Hazan V; Kark JD
Breast Cancer Res Treat; 2016 Jul; 158(1):157-167. PubMed ID: 27306419
[TBL] [Abstract][Full Text] [Related]
37. Body mass index and prognosis of breast cancer: An analysis by menstruation status when breast cancer diagnosis.
Sun L; Zhu Y; Qian Q; Tang L
Medicine (Baltimore); 2018 Jun; 97(26):e11220. PubMed ID: 29952978
[TBL] [Abstract][Full Text] [Related]
38. Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.
Aihara T; Yokota I; Hozumi Y; Aogi K; Iwata H; Tamura M; Fukuuchi A; Makino H; Kim R; Andoh M; Tsugawa K; Ohno S; Yamaguchi T; Ohashi Y; Watanabe T; Takatsuka Y; Mukai H
Breast Cancer Res Treat; 2014 Nov; 148(2):337-43. PubMed ID: 25318924
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
Li L; Chang B; Jiang X; Fan X; Li Y; Li T; Wu S; Zhang J; Kariminia S; Li Q
BMC Cancer; 2018 Oct; 18(1):977. PubMed ID: 30314452
[TBL] [Abstract][Full Text] [Related]
40. Body Mass Index at Diagnosis as a Prognostic Factor for Early-Stage Invasive Breast Cancer after Surgical Resection.
Wang X; Hui TL; Wang MQ; Liu H; Li RY; Song ZC
Oncol Res Treat; 2019; 42(4):195-201. PubMed ID: 30852575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
